Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Human metapneumovirus activates NOD-like receptor protein 3 inflammasome via its small hydrophobic protein which plays a detrimental role during infection in mice.

Lê VB, Dubois J, Couture C, Cavanagh MH, Uyar O, Pizzorno A, Rosa-Calatrava M, Hamelin MÈ, Boivin G.

PLoS Pathog. 2019 Apr 9;15(4):e1007689. doi: 10.1371/journal.ppat.1007689. eCollection 2019 Apr.

2.

Design and Validation with Influenza A Virus of an Aerosol Transmission Chamber for Ferrets.

Turgeon N, Hamelin MÈ, Verreault D, Lévesque A, Rhéaume C, Carbonneau J, Checkmahomed L, Girard M, Boivin G, Duchaine C.

Int J Environ Res Public Health. 2019 Feb 19;16(4). pii: E609. doi: 10.3390/ijerph16040609.

3.

Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.

Pizzorno A, Terrier O, Nicolas de Lamballerie C, Julien T, Padey B, Traversier A, Roche M, Hamelin ME, Rhéaume C, Croze S, Escuret V, Poissy J, Lina B, Legras-Lachuer C, Textoris J, Boivin G, Rosa-Calatrava M.

Front Immunol. 2019 Jan 29;10:60. doi: 10.3389/fimmu.2019.00060. eCollection 2019.

4.

OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.

Del Campo J, Pizzorno A, Djebali S, Bouley J, Haller M, Pérez-Vargas J, Lina B, Boivin G, Hamelin ME, Nicolas F, Le Vert A, Leverrier Y, Rosa-Calatrava M, Marvel J, Hill F.

NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4. eCollection 2019.

5.

Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice.

Lê BV, Jandrot-Perrus M, Couture C, Checkmahomed L, Venable MC, Hamelin MÈ, Boivin G.

J Gen Virol. 2018 Oct;99(10):1367-1380. doi: 10.1099/jgv.0.001135. Epub 2018 Aug 10.

PMID:
30102144
6.

Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections.

Lê VB, Riteau B, Alessi MC, Couture C, Jandrot-Perrus M, Rhéaume C, Hamelin MÈ, Boivin G.

Br J Pharmacol. 2018 Jan;175(2):388-403. doi: 10.1111/bph.14084. Epub 2017 Dec 10.

7.

Mutations in the fusion protein heptad repeat domains of human metapneumovirus impact on the formation of syncytia.

Dubois J, Cavanagh MH, Terrier O, Hamelin MÈ, Lina B, Shi R, Rosa-Calatrava M, Boivin G.

J Gen Virol. 2017 Jun;98(6):1174-1180. doi: 10.1099/jgv.0.000796. Epub 2017 Jun 14.

PMID:
28613142
8.

Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets.

Ann J, Abed Y, Beaulieu E, Bouhy X, Joly MH, Dubé K, Carbonneau J, Hamelin ME, Mallett C, Boivin G.

Influenza Other Respir Viruses. 2016 Mar;10(2):122-6. doi: 10.1111/irv.12356. Epub 2016 Jan 29.

9.

Use of a Multimodal Implementation Strategy to Improve Delirium Screening by Nurses on an Acute Care for Elders Unit.

Afriyie-Boateng M, Loftus C, Hamelin MA.

Worldviews Evid Based Nurs. 2015 Dec;12(6):389-91. doi: 10.1111/wvn.12120. Epub 2015 Oct 13.

PMID:
26460598
10.

Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection.

Rogers MB, Song T, Sebra R, Greenbaum BD, Hamelin ME, Fitch A, Twaddle A, Cui L, Holmes EC, Boivin G, Ghedin E.

MBio. 2015 Apr 7;6(2). pii: e02464-14. doi: 10.1128/mBio.02464-14.

11.

Effect of in vitro syncytium formation on the severity of human metapneumovirus disease in a murine model.

Aerts L, Cavanagh MH, Dubois J, Carbonneau J, Rhéaume C, Lavigne S, Couture C, Hamelin MÈ, Boivin G.

PLoS One. 2015 Mar 24;10(3):e0120283. doi: 10.1371/journal.pone.0120283. eCollection 2015.

12.

Adjuvant effect of the human metapneumovirus (HMPV) matrix protein in HMPV subunit vaccines.

Aerts L, Rhéaume C, Carbonneau J, Lavigne S, Couture C, Hamelin MÈ, Boivin G.

J Gen Virol. 2015 Apr;96(Pt 4):767-74. doi: 10.1099/vir.0.000031. Epub 2014 Dec 17.

PMID:
25519171
13.

Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.

Ann J, Samant M, Rheaume C, Dumas C, Beaulieu E, Morasse A, Mallett C, Hamelin ME, Papadopoulou B, Boivin G.

Vaccine. 2014 Sep 29;32(43):5730-9. doi: 10.1016/j.vaccine.2014.08.029. Epub 2014 Aug 27.

PMID:
25173481
14.

Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.

Pizzorno A, Abed Y, Plante PL, Carbonneau J, Baz M, Hamelin MÈ, Corbeil J, Boivin G.

Antimicrob Agents Chemother. 2014 Nov;58(11):6398-405. doi: 10.1128/AAC.02956-14. Epub 2014 Aug 11.

15.

Human metapneumovirus viral load is an important risk factor for disease severity in young children.

Roussy JF, Carbonneau J, Ouakki M, Papenburg J, Hamelin MÈ, De Serres G, Boivin G.

J Clin Virol. 2014 Jun;60(2):133-40. doi: 10.1016/j.jcv.2014.03.001. Epub 2014 Mar 12.

PMID:
24686044
16.

Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease risk.

Skowronski DM, Hamelin ME, De Serres G, Janjua NZ, Li G, Sabaiduc S, Bouhy X, Couture C, Leung A, Kobasa D, Embury-Hyatt C, de Bruin E, Balshaw R, Lavigne S, Petric M, Koopmans M, Boivin G.

PLoS One. 2014 Jan 27;9(1):e86555. doi: 10.1371/journal.pone.0086555. eCollection 2014.

17.

Genetic diversity and molecular evolution of the major human metapneumovirus surface glycoproteins over a decade.

Papenburg J, Carbonneau J, Isabel S, Bergeron MG, Williams JV, De Serres G, Hamelin MÈ, Boivin G.

J Clin Virol. 2013 Nov;58(3):541-7. doi: 10.1016/j.jcv.2013.08.029. Epub 2013 Sep 4.

PMID:
24041471
18.

Modulation of protease activated receptor 1 influences human metapneumovirus disease severity in a mouse model.

Aerts L, Hamelin MÈ, Rhéaume C, Lavigne S, Couture C, Kim W, Susan-Resiga D, Prat A, Seidah NG, Vergnolle N, Riteau B, Boivin G.

PLoS One. 2013 Aug 28;8(8):e72529. doi: 10.1371/journal.pone.0072529. eCollection 2013.

19.

Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice.

Lévy C, Aerts L, Hamelin MÈ, Granier C, Szécsi J, Lavillette D, Boivin G, Cosset FL.

Vaccine. 2013 Jun 7;31(25):2778-85. doi: 10.1016/j.vaccine.2013.03.051. Epub 2013 Apr 11.

PMID:
23583815
20.

Health questions posed by Amerindians in Guyana's deep interior.

Deonandan R, Vineberg B, Stulberg R, Jaleel M, Szecket N, Sheila D, Hamelin MA, Van der Kuur M, Zelcer S.

Glob J Health Sci. 2012 Aug 22;4(6):43-6. doi: 10.5539/gjhs.v4n6p43.

21.

Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission.

Ghedin E, Holmes EC, DePasse JV, Pinilla LT, Fitch A, Hamelin ME, Papenburg J, Boivin G.

J Infect Dis. 2012 Nov 15;206(10):1504-11. doi: 10.1093/infdis/jis571. Epub 2012 Sep 10.

22.

Microscale investigation of anaerobic biogas production under various hydrodynamic conditions.

Zhang JB, Wu J, Poncin S, Hamelin M, Li HZ.

Environ Sci Technol. 2012 Aug 21;46(16):8698-704. doi: 10.1021/es3013722. Epub 2012 Aug 6.

PMID:
22823100
23.

Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance.

Skowronski DM, Hamelin ME, Janjua NZ, De Serres G, Gardy JL, Rhéaume C, Bouhy X, Boivin G.

PLoS One. 2012;7(6):e38929. doi: 10.1371/journal.pone.0038929. Epub 2012 Jun 22.

24.

Seroconversion to seasonal influenza viruses after A(H1N1)pdm09 virus infection, Quebec, Canada.

Baz M, Papenburg J, Hamelin ME, Ouakki M, Skowronski DM, De Serres G, Boivin G.

Emerg Infect Dis. 2012 Jul;18(7):1132-4. doi: 10.3201/eid1807.111680.

25.

Catalase, a target of glycation damage in rat liver mitochondria with aging.

Bakala H, Hamelin M, Mary J, Borot-Laloi C, Friguet B.

Biochim Biophys Acta. 2012 Oct;1822(10):1527-34. doi: 10.1016/j.bbadis.2012.05.016. Epub 2012 Jun 7.

26.

Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children.

Papenburg J, Hamelin MÈ, Ouhoummane N, Carbonneau J, Ouakki M, Raymond F, Robitaille L, Corbeil J, Caouette G, Frenette L, De Serres G, Boivin G.

J Infect Dis. 2012 Jul 15;206(2):178-89. doi: 10.1093/infdis/jis333. Epub 2012 May 2.

PMID:
22551815
27.

Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010.

Skowronski DM, De Serres G, Janjua NZ, Gardy JL, Gilca V, Dionne M, Hamelin ME, Rhéaume C, Boivin G.

Euro Surveill. 2012 Jan 26;17(4). pii: 20066.

28.

Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010.

Papenburg J, Carbonneau J, Hamelin MÈ, Isabel S, Bouhy X, Ohoumanne N, Déry P, Paes BA, Corbeil J, Bergeron MG, De Serres G, Boivin G.

Emerg Infect Dis. 2012 Jan;18(1):120-4. doi: 10.3201/eid1801.110515.

29.

Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.

Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, Lanteigne AM, Hamelin ME, Mallett C, Papadopoulou B, Boivin G.

Clin Vaccine Immunol. 2012 Feb;19(2):209-18. doi: 10.1128/CVI.05441-11. Epub 2011 Dec 21.

30.

Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.

Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D.

Vaccine. 2011 Dec 9;30(1):35-41. doi: 10.1016/j.vaccine.2011.10.062. Epub 2011 Nov 7.

PMID:
22063386
31.

Molecular and antigenic evolution of human influenza A/H3N2 viruses in Quebec, Canada, 2009-2011.

Ann J, Papenburg J, Bouhy X, Rhéaume C, Hamelin MÈ, Boivin G.

J Clin Virol. 2012 Jan;53(1):88-92. doi: 10.1016/j.jcv.2011.09.016. Epub 2011 Oct 28.

PMID:
22036039
32.

The 2009 pandemic H1N1 D222G hemagglutinin mutation alters receptor specificity and increases virulence in mice but not in ferrets.

Abed Y, Pizzorno A, Hamelin ME, Leung A, Joubert P, Couture C, Kobasa D, Boivin G.

J Infect Dis. 2011 Oct 1;204(7):1008-16. doi: 10.1093/infdis/jir483.

PMID:
21881115
33.

Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.

Hamelin ME, Baz M, Bouhy X, Beaulieu E, Dubé K, Mallett C, Boivin G.

Antivir Ther. 2011;16(5):775-9. doi: 10.3851/IMP1794.

PMID:
21817200
34.

Long-term impairment of Streptococcus pneumoniae lung clearance is observed after initial infection with influenza A virus but not human metapneumovirus in mice.

Ludewick HP, Aerts L, Hamelin ME, Boivin G.

J Gen Virol. 2011 Jul;92(Pt 7):1662-5. doi: 10.1099/vir.0.030825-0. Epub 2011 Mar 16.

PMID:
21411678
35.

Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus.

Papenburg J, Baz M, Hamelin MÈ, Rhéaume C, Carbonneau J, Ouakki M, Rouleau I, De Serres G, Boivin G.

Clin Vaccine Immunol. 2011 Mar;18(3):520-2. doi: 10.1128/CVI.00449-10. Epub 2011 Jan 12.

36.

Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections.

Papenburg J, Baz M, Hamelin MÈ, Rhéaume C, Carbonneau J, Ouakki M, Rouleau I, Hardy I, Skowronski D, Roger M, Charest H, De Serres G, Boivin G.

Clin Infect Dis. 2010 Nov 1;51(9):1033-41. doi: 10.1086/656582.

PMID:
20887206
37.

Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets.

Hamelin ME, Baz M, Abed Y, Couture C, Joubert P, Beaulieu E, Bellerose N, Plante M, Mallett C, Schumer G, Kobinger GP, Boivin G.

PLoS Pathog. 2010 Jul 22;6(7):e1001015. doi: 10.1371/journal.ppat.1001015.

38.

Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model.

Hamelin ME, Gagnon C, Prince GA, Kiener P, Suzich J, Ulbrandt N, Boivin G.

Antiviral Res. 2010 Oct;88(1):31-7. doi: 10.1016/j.antiviral.2010.07.001. Epub 2010 Jul 7.

PMID:
20619294
39.

Contagious period for pandemic (H1N1) 2009.

De Serres G, Rouleau I, Hamelin ME, Quach C, Skowronski D, Flamand L, Boulianne N, Li Y, Carbonneau J, Bourgault A, Couillard M, Charest H, Boivin G.

Emerg Infect Dis. 2010 May;16(5):783-8. doi: 10.3201/eid1605.091894.

40.

Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada.

Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, Rosella LC, Dickinson JA, Gilca R, Sethi P, Ouhoummane N, Willison DJ, Rouleau I, Petric M, Fonseca K, Drews SJ, Rebbapragada A, Charest H, Hamelin ME, Boivin G, Gardy JL, Li Y, Kwindt TL, Patrick DM, Brunham RC; Canadian SAVOIR Team.

PLoS Med. 2010 Apr 6;7(4):e1000258. doi: 10.1371/journal.pmed.1000258.

41.
42.

Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.

Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G.

N Engl J Med. 2009 Dec 3;361(23):2296-7. doi: 10.1056/NEJMc0910060. Epub 2009 Nov 11. No abstract available.

PMID:
19907034
43.

Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia.

Kukavica-Ibrulj I, Hamelin ME, Prince GA, Gagnon C, Bergeron Y, Bergeron MG, Boivin G.

J Virol. 2009 Feb;83(3):1341-9. doi: 10.1128/JVI.01123-08. Epub 2008 Nov 19.

44.

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, Boivin G, Leclerc D.

Vaccine. 2008 Jun 25;26(27-28):3395-403. doi: 10.1016/j.vaccine.2008.04.052. Epub 2008 May 12.

PMID:
18511159
45.

The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice.

Hamelin ME, Couture C, Sackett M, Kiener P, Suzich J, Ulbrandt N, Boivin G.

Antivir Ther. 2008;13(1):39-46.

PMID:
18389897
46.

Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus.

Hamelin ME, Couture C, Sackett MK, Boivin G.

J Gen Virol. 2007 Dec;88(Pt 12):3391-400.

PMID:
18024909
47.

Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus.

Deffrasnes C, Hamelin ME, Prince GA, Boivin G.

Antimicrob Agents Chemother. 2008 Jan;52(1):279-87. Epub 2007 Oct 29.

48.

Glycation damage targets glutamate dehydrogenase in the rat liver mitochondrial matrix during aging.

Hamelin M, Mary J, Vostry M, Friguet B, Bakala H.

FEBS J. 2007 Nov;274(22):5949-61. Epub 2007 Oct 19.

49.

Human metapneumovirus.

Deffrasnes C, Hamelin ME, Boivin G.

Semin Respir Crit Care Med. 2007 Apr;28(2):213-21. Review.

PMID:
17458775
50.

An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility.

Boivin G, De Serres G, Hamelin ME, Côté S, Argouin M, Tremblay G, Maranda-Aubut R, Sauvageau C, Ouakki M, Boulianne N, Couture C.

Clin Infect Dis. 2007 May 1;44(9):1152-8. Epub 2007 Mar 28.

PMID:
17407031

Supplemental Content

Loading ...
Support Center